Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two new clinical trials compare Retevmo (selpercatinib) with other standard treatments for tumors with changes in the RET gene.
Better outcomes were achieved with combinations of experimental new drugs targeting common and rare tumour mutations.
New therapies tested delayed relapse and, in some cases, lengthened survival, for women with cervical, ovarian and endometrial cancers.
Researchers are investigating AI’s potential to transform cancer care and improve patient outcomes.
Adding checkpoint inhibitors to chemotherapy before surgery and continuing them alone afterward reduces the risk of recurrence and death.
The radiopharmaceutical doubled progression-free survival time from six to 12 months.
Cabometyx improved progression-free survival versus placebo in people with neuroendocrine tumors inside or outside the pancreas.
People who received the targeted therapy after surgery were less likely to experience recurrence or brain metastasis.
A chemotherapy-free regimen combining immunotherapy with an antibody-drug conjugate extended survival by 15 months.
Patients previously treated with immune checkpoint inhibitors and anti-angiogenics showed improved progression free survival.
The checkpoint inhibitor is now indicated for pre- and post-surgery treatment of Stage II or III non-small-cell lung cancer.
Other studies focused on bladder cancer, prostate cancer and liquid biopsies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.